Media coverage about CONMED (NASDAQ:CNMD) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CONMED earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 46.8077672297611 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- $212.38 Million in Sales Expected for CONMED Co. (CNMD) This Quarter (americanbankingnews.com)
- CONMED Corp. : CNMD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017 (finance.yahoo.com)
- CONMED Corporation to Present at the J.P. Morgan Healthcare Conference (finance.yahoo.com)
- CONMED Corporation (CNMD) Expected to Announce Earnings of $0.65 Per Share (americanbankingnews.com)
- CONMED (CNMD) Downgraded to Sell at BidaskClub (americanbankingnews.com)
A number of research analysts recently issued reports on CNMD shares. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of CONMED in a report on Friday, November 17th. KeyCorp reiterated a “hold” rating on shares of CONMED in a report on Friday, November 3rd. Piper Jaffray Companies reiterated a “hold” rating and issued a $46.00 target price on shares of CONMED in a report on Friday, November 3rd. Zacks Investment Research upgraded CONMED from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Finally, BidaskClub downgraded CONMED from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $50.67.
CONMED (NASDAQ:CNMD) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. The company had revenue of $190.10 million during the quarter, compared to the consensus estimate of $187.13 million. CONMED had a return on equity of 8.40% and a net margin of 1.99%. CONMED’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.41 EPS. sell-side analysts predict that CONMED will post 1.84 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 5th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date is Thursday, December 14th. CONMED’s dividend payout ratio (DPR) is 142.86%.
In other CONMED news, EVP Luke A. Pomilio sold 29,363 shares of CONMED stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $50.70, for a total transaction of $1,488,704.10. Following the completion of the sale, the executive vice president now directly owns 45,486 shares of the company’s stock, valued at approximately $2,306,140.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Luke A. Pomilio sold 12,429 shares of CONMED stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $50.63, for a total value of $629,280.27. Following the sale, the chief financial officer now directly owns 45,486 shares of the company’s stock, valued at $2,302,956.18. The disclosure for this sale can be found here. Insiders have sold a total of 51,812 shares of company stock valued at $2,654,756 over the last ninety days. 2.62% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/22/conmed-cnmd-earns-media-sentiment-rating-of-0-11.html.
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.